Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-04-03Clinical Trial Update: Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers [Phase 1, Phase 2]
Phase 1/2 trial evaluating transplantation of umbilical cord blood after chemotherapy for acute blood cancers; trial terminated with results…
-
CLINICAL_TRIALS trial_result · 2019-03-20Clinical Trial Update: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) [Phase 3]
A Phase 3 trial evaluating US-ATG-F to prevent chronic graft-versus-host disease in hematologic malignancy patients has completed with resul…
-
CLINICAL_TRIALS trial_result · 2019-03-19Clinical Trial Update: Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML [Phase 2]
Phase 2 clinical trial evaluating sequential intensive chemotherapy followed by reduced-intensity conditioning for refractory and relapsed a…
-
CLINICAL_TRIALS trial_result · 2019-03-18Clinical Trial Update: A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia [Phase 1]
Phase 1 study of PF-06747143 as a single agent or with standard chemotherapy in adult acute myeloid leukemia was terminated with results pos…
-
CLINICAL_TRIALS trial_result · 2019-03-05Clinical Trial Update: A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations [Phase 1, Phase 2]
Clinical trial update for E6201 in advanced hematologic malignancies with FLT3 and/or Ras mutations (Phase 1/2) shows terminated status; res…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-02-28Clinical Trial Update: An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy [Phase 2, Phase 3]
Phase 2/3 trial evaluating decitabine with talacotuzumab versus decitabine alone in adults with acute myeloid leukemia ineligible for intens…
-
CLINICAL_TRIALS trial_result · 2019-02-28Clinical Trial Update: Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML [Phase 1, Phase 2]
A trial evaluating the combination of ruxolitinib and decitabine in accelerated phase myeloproliferative neoplasms or post-MPN acute myeloid…
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies [Phase 1, Phase 2]
A pilot Phase 1/2 study evaluating safety and efficacy of NiCord and UNM CBU in patients with various hematologic malignancies has completed…
-
CLINICAL_TRIALS trial_result · 2019-02-21Clinical Trial Update: CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies [Phase 1]
This update reports the completion of a Phase 1 study of CAMELLIA, an anti-CD47 antibody therapy, in hematologic malignancies.
-
CLINICAL_TRIALS trial_result · 2019-02-20Clinical Trial Update: Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Update on a dose-escalation study of gilteritinib (ASP2215) assessing safety, tolerability, and pharmacokinetics/pharmacodynamics in relapse…
-
CLINICAL_TRIALS withdrawal · 2019-02-20Clinical Trial Update: Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) [Phase 1, Phase 2]
The clinical trial evaluating the combination of azacitidine and avelumab in patients with acute myeloid leukemia and minimal residual disea…
-
CLINICAL_TRIALS trial_result · 2019-02-18Clinical Trial Update: Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating the safety and preliminary efficacy of combining azacitidine with gemtuzumab ozogamicin in relapsed a…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) [Phase 1]
Completed Phase 1 study evaluating quizartinib (AC220) given after stem cell transplant in patients with acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Phase 1 Study of Quizartinib [Phase 1]
The document describes the completion of a Phase 1 trial of quizartinib in relapsed or refractory acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) [Phase 1]
Phase 1 study evaluating AC220 (quizartinib) in combination with induction and consolidation therapy for newly diagnosed acute myeloid leuke…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT [Phase 2]
Phase 2 bridging study evaluating elimination of minimal residual disease before hematopoietic cell transplantation in acute leukemia; study…
-
CLINICAL_TRIALS trial_result · 2019-02-08Clinical Trial Update: Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) [Phase 2]
Phase 2 trial results (EFFIKIR) evaluating an anti-KIR monoclonal antibody as maintenance therapy in adults with acute myeloid leukemia have…
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) [Phase 1]
A Phase 1 trial evaluating Volasertib plus Decitabine in adults with acute myeloid leukemia has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine [Phase 1, Phase 2]
This trial update covers a Phase 1/Phase 2 study of laromustine combined with infusional cytarabine in elderly patients with acute myeloid l…
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations [Phase 1]
Phase 1 trial evaluating pacritinib in combination with chemotherapy for adults with acute myeloid leukemia, including FLT3-mutant AML; the …
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS [Phase 1]
Phase 1 clinical trial evaluating Yttrium-90 anti-CD45 monoclonal antibody BC8 followed by donor stem cell transplant in patients with high-…
-
CLINICAL_TRIALS trial_result · 2019-01-24Clinical Trial Update: Red Cell Transfusion Goals in Patients With Acute Leukemias [Phase 1]
Phase 1 trial completed evaluating red blood cell transfusion goals in patients with acute leukemias (acute lymphoblastic leukemia, acute my…
-
CLINICAL_TRIALS trial_result · 2019-01-24Clinical Trial Update: Epigenetic Reprogramming in Relapse AML [Phase 1]
A Phase 1 trial evaluating epigenetic reprogramming for relapse acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating inducible regulatory T cells (iTregs) in non-myeloablative sibling donor peripheral blood stem cell transplantation…
-
FDA approval · 2019-01-18FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s original application for a generic cyclophosphamide product. This marks approval of a generic formulation …